Krystal Biotech, Inc. (KRYS)
NASDAQ:KRYS
Want to see KRYS full AI Analyst Report?
Total Valuation
Krystal Biotech has a market cap or net worth of $9.03B. The enterprise value is $8.10B.
Market Cap$9.03B
Enterprise Value$8.10B
Share Statistics
Krystal Biotech has 29,479,755 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,479,755
Owned by Insiders11.31%
Owned by Institutions32.59%
Financial Efficiency
Krystal Biotech’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 13.09%.
Return on Equity (ROE)0.17
Return on Assets (ROA)0.15
Return on Invested Capital (ROIC)13.09%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee1.42M
Profits Per Employee744.84K
Employee Count275
Asset Turnover0.29
Inventory Turnover0.71
Valuation Ratios
The current PE Ratio of Krystal Biotech is 33.8. Krystal Biotech’s PEG ratio is 0.27.
PE Ratio33.8
PS Ratio18.34
PB Ratio5.85
Price to Fair Value5.85
Price to FCF37.77
Price to Operating Cash Flow34.14
PEG Ratio0.27
Income Statement
In the last 12 months, Krystal Biotech had revenue of 389.13M and earned 204.83M in profits. Earnings per share was 7.08.
Revenue389.13M
Gross Profit360.36M
Operating Income161.29M
Pretax Income189.47M
Net Income204.83M
EBITDA167.85M
Earnings Per Share (EPS)7.08
Cash Flow
In the last 12 months, operating cash flow was 250.28M and capital expenditures -12.89M, giving a free cash flow of 237.38M billion.
Operating Cash Flow250.28M
Free Cash Flow237.38M
Free Cash Flow per Share8.05
Dividends & Yields
Krystal Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.79
52-Week Price Change120.54%
50-Day Moving Average269.50
200-Day Moving Average226.00
Relative Strength Index (RSI)53.55
Average Volume (3m)298.70K
Important Dates
Krystal Biotech upcoming earnings date is Aug 10, 2026, Before Open (Confirmed).
Last Earnings DateMay 4, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date―
Financial Position
Krystal Biotech as a current ratio of 9.95, with Debt / Equity ratio of 0.14%
Current Ratio9.95
Quick Ratio9.56
Debt to Market Cap0.00
Net Debt to EBITDA-2.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Krystal Biotech has paid -15.36M in taxes.
Income Tax-15.36M
Effective Tax Rate-0.08
Enterprise Valuation
Krystal Biotech EV to EBITDA ratio is 39.61, with an EV/FCF ratio of 35.20.
EV to Sales17.09
EV to EBITDA39.61
EV to Free Cash Flow35.20
EV to Operating Cash Flow33.10
Balance Sheet
Krystal Biotech has $823.40M in cash and marketable securities with $1.80M in debt, giving a net cash position of $821.61M billion.
Cash & Marketable Securities$823.40M
Total Debt$1.80M
Net Cash$821.61M
Net Cash Per Share$27.87
Tangible Book Value Per Share$42.14
Margins
Gross margin is 92.79%, with operating margin of 41.45%, and net profit margin of 52.64%.
Gross Margin92.79%
Operating Margin41.45%
Pretax Margin48.69%
Net Profit Margin52.64%
EBITDA Margin43.13%
EBIT Margin41.45%
Analyst Forecast
The average price target for Krystal Biotech is $316.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$316.00
Price Target Upside15.24% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast25.15%
EPS Growth Forecast79.56%